Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | KIT | P10721 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL944085 | 0.80 | CCNT1 (0.50) | AXLNTRK1PDPK1 | |
| SCHEMBL3197156 | 0.77 | ABL1 (0.39) | — | |
| SCHEMBL982016 | 0.75 | MAP4K4 (0.68) | MAP4K4MEN1PSIP1AXLMKNK1 | |
| SCHEMBL11622212 | 0.75 | MAP4K4 (0.68) | MAP4K4MEN1PSIP1AXLMKNK1 | |
| SCHEMBL13653889 | 0.74 | KDM4E (0.40) | MEN1CA12CA1CA2CA9 | |
| SCHEMBL6222939 | 0.72 | ALOX5AP (0.33) | — | |
| SCHEMBL3414793 | 0.72 | MAP4K4 (0.58) | MAP4K4MKNK1MKNK2CYP3A4PGR | |
| SCHEMBL956760 | 0.72 | GSK3B (0.45) | MKNK1MKNK2 | |
| SCHEMBL30098552 | 0.71 | MAP4K4 (0.68) | MAP4K4MEN1PSIP1AXLMKNK1 | |
| SCHEMBL2081751 | 0.71 | MAP4K4 (0.68) | MAP4K4MEN1PSIP1AXLMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312334-B2 | Method of preparing inhibitors phosphodiesterase-4 | MERCK & CO. INC. (US) | 2007-12-25 | — | — | US | disclosed |
| CN-1326856-C | Method of preparing inhibitors of phosphodiesterase-4 | MERCK & CO INC (US) | 2007-07-18 | — | — | CN | disclosed |
| US-20060040981-A1 | Use of phosphodiesterase-4 inhibitors as enhancers of cognition | MERCK FROSST CANADA LTD. (CA) | 2006-02-23 | — | — | US | disclosed |
| CN-1738818-A | Process for preparing phosphodiesterase-4 inhibitors | MERCK & CO INC (US) | 2006-02-22 | — | — | CN | disclosed |
| US-20060019981-A1 | Method of preparing inhibitors phosphodiesterase-4 | MERCK & CO., INC. | 2006-01-26 | — | — | US | disclosed |
| EP-1592419-A1 | USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION | Merck Frosst Canada & Co. (CA) | 2005-11-09 | — | — | EP | disclosed |
| EP-1397359-B1 | 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-08-31 | — | — | EP | disclosed |
| US-6909002-B2 | Method of preparing inhibitors of phosphodiesterase-4 | MERCK & CO., INC. (US) | 2005-06-21 | — | — | US | disclosed |
| WO-2004047836-A1 | USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | disclosed |
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
| US-6677351-B2 | USEFUL IN TREATMENT OF ASTHMA AND INFLAMMATION | MERCK FROSST CANADA & CO. (CA) | 2004-01-13 | — | — | US | disclosed |
| US-20030096829-A1 | 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102472-A1 | Method of preparing inhibitors of phosphodiesterase-4 | PDE4B, PDE4A, PDE5A | MAP4K4 1116/4885MEN1 798/4885PSIP1 450/4885 |
| US-20030096829-A1 | 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE7A | MAP4K4 681/4885MEN1 3789/4885PSIP1 325/4885 |
| US-20060019981-A1 | Method of preparing inhibitors phosphodiesterase-4 | PDE4A, PDE5A, PDE3A | MAP4K4 1105/4885MEN1 1362/4885PSIP1 757/4885 |
| US-20060040981-A1 | Use of phosphodiesterase-4 inhibitors as enhancers of cognition | PDE4A, PDE4B, PDE4C | MAP4K4 357/4885MEN1 3307/4885PSIP1 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.